Related Experiment Videos
Mucocutaneous leishmaniasis and HIV
E S Miralles1, M Núñez, Y Hilara
1Servicio de Dermatología, Universidad de Alcalá de Henares, Hospital Ramón y Cajal, Madrid, Spain.
Dermatology (Basel, Switzerland)
|January 1, 1994
Summary
This case study highlights a rare instance of mucocutaneous leishmaniasis in Europe, co-occurring with HIV infection. Treatment with meglumine antimonate showed positive results in this unique patient presentation.
Area of Science:
- Infectious Diseases
- Immunology
- Dermatology
Background:
- Mucocutaneous leishmaniasis is uncommon in Europe and characterized by frequent relapses.
- Visceral leishmaniasis is more common in HIV patients, often with poor treatment outcomes.
- Co-infection of mucocutaneous leishmaniasis and HIV is rarely documented.
Observation:
- A patient presented with a centrofacial granuloma, diagnosed as mucocutaneous leishmaniasis.
- Concurrently, the patient was diagnosed with Human Immunodeficiency Virus (HIV) infection.
- This represents a rare case of leishmaniasis acquired in Europe.
Findings:
- Intravenous meglumine antimonate at 20 mg/kg/day for 28 days was administered.
- The treatment regimen proved effective for the patient's condition.
Implications:
- This case expands the understanding of leishmaniasis presentation in HIV-infected individuals in Europe.
- It suggests meglumine antimonate as a viable treatment option for this rare co-infection.
- Highlights the importance of considering leishmaniasis in patients with granulomatous lesions and HIV.